Regeneron Plans to Launch Late Stage Obesity Trials and Cholesterol Drug Combination Studies
Regeneron Pharmaceuticals Inc. is moving its experimental weight-loss drug olatorepatide into late-stage trials this year while exploring combination therapies.
Insights:
Regeneron Pharmaceuticals, Inc. executives voiced confidence in the experimental weight-loss drug olatorepatide on a post-earnings call. The company announced it plans this year to start late-stage trials of olatorepatide for obesity in patients with and without Type 2 diabetes. Additionally, Regeneron Pharmaceuticals, Inc.said it plans to initiate studies evaluating olatorepatide in combination with the cholesterol drug Praluent.
